Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition
暂无分享,去创建一个
D. Holtzman | G. Bu | J. Cirrito | Na Zhao | Chia-Chen Liu | T. Kanekiyo | Jian Wang | Jin Hu | Na Wang
[1] E. Hol,et al. Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease , 2016, Progress in Neurobiology.
[2] Bradley T. Hyman,et al. Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.
[3] G. Bu,et al. Apolipoprotein E lipoprotein particles inhibit amyloid-β uptake through cell surface heparan sulphate proteoglycan , 2016, Molecular Neurodegeneration.
[4] B. Zlokovic,et al. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. , 2016, Biochimica et biophysica acta.
[5] D. Holtzman,et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease , 2016, Science Translational Medicine.
[6] T. Bayer,et al. Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier. , 2015, The Journal of clinical investigation.
[7] G. Hu,et al. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits , 2015, Molecular Neurodegeneration.
[8] B. Zlokovic,et al. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer’s disease: the role, regulation and restoration of LRP1 , 2015, Front. Aging Neurosci..
[9] I. Lombardo,et al. The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.
[10] G. Bu,et al. Neuronal LRP1 Regulates Glucose Metabolism and Insulin Signaling in the Brain , 2015, The Journal of Neuroscience.
[11] Huaxi Xu,et al. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice , 2015, Molecular Neurodegeneration.
[12] J. Rogers,et al. Deficiency in LRP6-Mediated Wnt Signaling Contributes to Synaptic Abnormalities and Amyloid Pathology in Alzheimer’s Disease , 2014, Neuron.
[13] Qingli Xiao,et al. Enhancing Astrocytic Lysosome Biogenesis Facilitates Aβ Clearance and Attenuates Amyloid Plaque Pathogenesis , 2014, The Journal of Neuroscience.
[14] Jianmiao Liu,et al. Mechanisms of U87 Astrocytoma Cell Uptake and Trafficking of Monomeric versus Protofibril Alzheimer’s Disease Amyloid-β Proteins , 2014, PloS one.
[15] G. Bu,et al. The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease , 2014, Front. Aging Neurosci..
[16] Pritam Das,et al. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease. , 2014, Brain : a journal of neurology.
[17] R. Maccioni,et al. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches , 2014, Front. Cell. Neurosci..
[18] G. Bu,et al. Retinoic Acid Isomers Facilitate Apolipoprotein E Production and Lipidation in Astrocytes through the Retinoid X Receptor/Retinoic Acid Receptor Pathway* , 2014, The Journal of Biological Chemistry.
[19] D. Holtzman,et al. Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 , 2013, The Journal of Neuroscience.
[20] H. Emonard,et al. LRP-1: A Checkpoint for the Extracellular Matrix Proteolysis , 2013, BioMed research international.
[21] M. Meraz-Ríos,et al. Inflammatory process in Alzheimer's Disease , 2013, Front. Integr. Neurosci..
[22] A. Shah,et al. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions , 2013, Proceedings of the National Academy of Sciences.
[23] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[24] Huaxi Xu,et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.
[25] Andrew W. Kraft,et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] D. Holtzman,et al. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis , 2012, The Journal of experimental medicine.
[27] Jie Li,et al. LRP1 in Brain Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's Amyloid-β , 2012, The Journal of Neuroscience.
[28] Jie Li,et al. Differential Regulation of Amyloid-β Endocytic Trafficking and Lysosomal Degradation by Apolipoprotein E Isoforms*♦ , 2012, The Journal of Biological Chemistry.
[29] T. Golde,et al. Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology , 2012, Molecular Neurodegeneration.
[30] M. Leissring,et al. Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.
[31] D. Borchelt,et al. Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice , 2012, Alzheimer's Research & Therapy.
[32] G. Hu,et al. Aquaporin-4 mediates astrocyte response to β-amyloid , 2012, Molecular and Cellular Neuroscience.
[33] Daniel R. Dries,et al. Extracting β-amyloid from Alzheimer's disease , 2012, Proceedings of the National Academy of Sciences.
[34] M. Blankenstein,et al. The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes , 2012, Experimental Neurology.
[35] B. Zlokovic. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.
[36] J. Growdon,et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. , 2011, The American journal of pathology.
[37] M. Mintun,et al. Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans , 2011, Proceedings of the National Academy of Sciences.
[38] Hui Zheng,et al. Biology and pathophysiology of the amyloid precursor protein , 2011, Molecular Neurodegeneration.
[39] G. Bu,et al. Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations , 2011, Journal of Neuroscience Methods.
[40] G. Bu,et al. Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-β Uptake , 2011, The Journal of Neuroscience.
[41] J. Morris,et al. Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.
[42] M. Sofroniew,et al. Astrocytes: biology and pathology , 2009, Acta Neuropathologica.
[43] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[44] D. Holtzman,et al. Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis , 2009, The Journal of Neuroscience.
[45] Heesang Song,et al. Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. , 2009, Cancer research.
[46] D. Holtzman,et al. The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid β Peptides in an in Vitro Model of the Blood-Brain Barrier Cells* , 2008, Journal of Biological Chemistry.
[47] A. Bordey,et al. The astrocyte odyssey , 2008, Progress in Neurobiology.
[48] D. Holtzman,et al. ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.
[49] L. Muglia,et al. Amyloid Precursor Protein Regulates Brain Apolipoprotein E and Cholesterol Metabolism through Lipoprotein Receptor LRP1 , 2007, Neuron.
[50] A. Goate,et al. Clearance of amyloid-β by circulating lipoprotein receptors , 2007, Nature Medicine.
[51] D. Holtzman,et al. Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.
[52] Tony Wyss-Coray,et al. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.
[53] M. Fornerod,et al. Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.
[54] Yonghe Li,et al. Rapid Endocytosis of the Low Density Lipoprotein Receptor-related Protein Modulates Cell Surface Distribution and Processing of the β-Amyloid Precursor Protein* , 2005, Journal of Biological Chemistry.
[55] S. Paul,et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.
[56] Bruce J Aronow,et al. ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.
[57] Joanna L. Jankowsky,et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase , 2004 .
[58] D. Selkoe,et al. Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.
[59] D. Holtzman,et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life , 2003, The Journal of Neuroscience.
[60] William C Hahn,et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. , 2003, RNA.
[61] D. Selkoe,et al. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics , 2002, Science.
[62] D. Gutmann,et al. Astrocyte-Specific Inactivation of the Neurofibromatosis 1 Gene (NF1) Is Insufficient for Astrocytoma Formation , 2002, Molecular and Cellular Biology.
[63] D. Strickland,et al. LRP: a multifunctional scavenger and signaling receptor. , 2001, The Journal of clinical investigation.
[64] R. Katzman.,et al. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. , 2000, The Journal of clinical investigation.
[65] B. Hyman,et al. Modulation of β-Amyloid Precursor Protein Processing by the Low Density Lipoprotein Receptor-related Protein (LRP) , 2000, The Journal of Biological Chemistry.
[66] R. Hammer,et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. , 1998, The Journal of clinical investigation.
[67] Michael J. Cullen,et al. Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.
[68] H. Geuze,et al. 39 kDa receptor‐associated protein is an ER resident protein and molecular chaperone for LDL receptor‐related protein. , 1995, The EMBO journal.
[69] T. Bayer,et al. Endothelial LRP 1 transports amyloid-β 1 – 42 across the blood-brain barrier , 2015 .
[70] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[71] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[72] A. Goate,et al. Clearance of amyloid-beta by circulating lipoprotein receptors. , 2007, Nature medicine.
[73] D. Borchelt,et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. , 2004, Human molecular genetics.
[74] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.
[75] Opposing effects of , 2022 .